The results indicated that HCP5 was up-regulated in most cancers, including cholangio carcinoma (CHOL), esophageal carcinoma (ESCA), acute myeloid leukemia (LAML) and pancreatic adenocarcinoma (PAAD) (|log2FC| Cutoff: 1, P-value Cutoff: 0.01, Fig. 6). Here, HCP5 is linked to carcinoma of esophagus.